Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions

Abstract

Objective

This study evaluated the role of cetirizine compared to diphenhydramine as premedications for patients receiving paclitaxel, cetuximab, and rituximab infusions. Historically, diphenhydramine has been linked with more sedation in comparison to cetirizine; however, it is unknown if cetirizine can replace diphenhydramine in the prevention of hypersensitivity reactions in patients receiving chemotherapy.

Methods

This is a retrospective study designed to assess infusion reactions occurring in patients receiving diphenhydramine or cetirizine premedication for rituximab, paclitaxel, or cetuximab therapies. Infusion reactions were defined as various symptoms such as flushing, itching, alterations in heart rate and blood pressure, and dyspnea plus the clinical setting of a concurrent or very recent infusion.

Results

A total of 207 patients were evaluated in this study with 83 patients receiving cetirizine and 124 diphenhydramine patients. Overall, the percentage of patients with at least one chemotherapy-related infusion event in the cetirizine group was 19.3% (95% CI 11.4–29.4) compared to diphenhydramine group 24.2% (95% CI 17.0–32.7), P = 0.40. Of the patients who received cetirizine and then experienced an event in the first cycle, 41.7% (95% CI 13.7–74.3) of the events were due to paclitaxel, 50.0% (95% CI 19.4–80.6) were due to rituximab, and 8.3% (95% CI 0.1–43.6) were due to cetuximab. Of the patients who received diphenhydramine and then experienced an event in the first cycle, 26.1% (95% CI 5.7–51.4) were due to paclitaxel, 73.9% (95% CI 48.6–94.3) were due to rituximab and none due to cetuximab.

Conclusion

Cetirizine appears to be a viable substitute for diphenhydramine for the prevention of infusions reactions with cetuximab, paclitaxel, and rituximab infusions in adults. Prospective studies are needed to determine the efficacy and safety of cetirizine compared with diphenhydramine in the prevention of chemotherapy-related infusion reactions.

Keywords

Cetirizine chemotherapy diphenhydramine infusion reaction premedication

Get full access to this article

View all access options for this article.

References

Grandvuillemin

Disson-Dautriche

Miremont-Salame

et al.

Cetuximab infusion reactions: French pharmacovigilance database analysis. J Oncol Pharm Pract 2013; 19: 130–137.

Grillo-López

White

Varns

et al.

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66–66.

Syrigou

Dannos

Kotteas

et al.

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011; 156: 320–320.

Shepherd

. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253–262.

Siena

Glynne-Jones

Adenis

et al.

Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010; 116: 1827–1837.

Dillman

Hendrix

. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003; 1: 38–48.

Lenz

. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601–609.

Meltzer

. Performance effects of antihistamines. J Allergy Clin Immunol 1990; 86: 613–619.

Weiler

Bloomfield

Woodworth

et al.

Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000; 132: 354–363.

10.

Schroeck

Ford

Conway

et al.

Review of safety and efficacy of sleep medicines in older adults. Clin Ther 2016; 38: 2340–2370.

11.

Asero

. Cetirizine premedication prevents acute urticaria induced by weak COX-1 inhibitors in multiple NSAID reactors. Eur Ann Allergy Clin Immunol 2010; 42: 174–177.

12.

Albert

Hallmark

Sakmar

et al.

Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm 1975; 5: 159–170.

13.

Banerji

Long

Camargo

Jr . Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc 2007; 28: 418–426.

14.

Simons

. Advances in H₂-antihistamines. N Engl J Med 2004; 351: 2203–2217.

15.

Tenn

Steacy

et al.

Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score. Allergy Asthma Clin Immunol 2018; 16: 14–15.

16.

Lahdenne

Wikström

Aalto

et al.

Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken) 2010; 62: 785–790.

17.

Baur

van Oosterom

Diéras

et al.

A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2008; 134: 125–135.

18.

Park

Godbold

Chung

et al.

Comparison of cetirizine to diphenhydramine in the treatment of acute food allergic reactions. J Allergy Clin Immunol 2011; 128: 1127–1128.

19.

National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 10 May 2017).